Shift, Sentiment

A Shift in Sentiment: Major Banks Revise Stance on Synopsys Ahead of Earnings

09.12.2025 - 03:04:05

Synopsys US8716071076

Within a single day, two prominent Wall Street institutions have revised their outlook on shares of Synopsys Inc. Both Bank of America and Citi upgraded the electronic design automation (EDA) software leader, moving their ratings from "Underperform" to "Neutral." This shift in analyst sentiment arrives just before the company’s critical quarterly report, scheduled for December 10.

Bank of America not only adjusted its rating but also established a price target of $500 per share. This figure implies an approximate 7% upside from recent trading levels. Citi mirrored this move, suggesting the upcoming earnings release could serve as a potential "clearing event" for the stock.

Market experts are looking for management to provide clarity on several pressing issues:
* Unexplained softness in the company's business operations in China.
* Challenges within its intellectual property (IP) segment related to Intel.
* The financial impact and integration costs associated with the recent Ansys acquisition.

A Strategic Partnership with NVIDIA

The analyst upgrades follow closely on the heels of a significant strategic announcement. Just one week prior, Synopsys revealed a partnership with NVIDIA, which includes a $2 billion equity investment by the chipmaker. NVIDIA will purchase shares at a price of $414.79 each. The collaboration focuses on integrating NVIDIA's CUDA, artificial intelligence technologies, and Omniverse platforms into Synopsys's product suite.

Should investors sell immediately? Or is it worth buying Synopsys?

However, Citi analysts provided a measured view of the deal, characterizing it as "tactical rather than exclusive." They noted that the partnership does not necessarily guarantee a sustainable long-term competitive advantage for Synopsys.

Divergent Views on Wall Street

The broader analyst community remains divided on the stock's prospects. While the consensus recommendation stands at "Moderate Buy" with an average price target of $553.67, individual firm assessments show a wide range:

  • Piper Sandler: $630 (Overweight)
  • KeyCorp: $575 (Overweight)
  • Robert W. Baird: $535 (Neutral)
  • Wells Fargo: $445 (Equal Weight)

All Eyes on Forward Guidance

When Synopsys reports its fourth-quarter and full-year fiscal 2025 results on December 10, the focus will extend beyond the historical figures. For Q4, management has provided earnings per share (EPS) guidance in the range of $2.76 to $2.80. The full-year forecast is for EPS between $12.76 and $12.80.

Analysts emphasize that the company's outlook for fiscal year 2026 will be far more consequential than the quarterly numbers. Citi stressed that only a "credible and achievable" forecast will be sufficient to alleviate investor concerns surrounding exposure to China and the Ansys integration. Notably, major institutional investors including Vanguard and State Street have recently increased their holdings significantly, collectively controlling over 85% of the company's outstanding shares.

Ad

Synopsys Stock: Buy or Sell?! New Synopsys Analysis from December 9 delivers the answer:

The latest Synopsys figures speak for themselves: Urgent action needed for Synopsys investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 9.

Synopsys: Buy or sell? Read more here...

@ boerse-global.de